Francois Cornelis1, Vlasios Sotirchos2, Elena Violari2, Constantinos T Sofocleous2, Heiko Schoder3, Jeremy C Durack2, Robert H Siegelbaum2, Majid Maybody2, John Humm4, Stephen B Solomon5. 1. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York Department of Radiology, Pellegrin Hospital, Bordeaux, France. 2. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York; and. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York solomons@mskcc.org.
Abstract
UNLABELLED: The rationale of this study was to examine whether (18)F-FDG PET/CT and contrast-enhanced CT performed immediately after percutaneous ablation of liver metastases are predictors of local treatment failure at 1 y. METHODS: This Health Insurance Portability and Accountability Act-compliant, Institutional Review Board-approved retrospective study reviewed 25 PET/CT-guided thermal ablations performed from September 2011 to March 2013 on 21 patients (11 women and 10 men; mean age, 56.8 y; range, 35-79 y) for the treatment of liver metastases (colorectal, n = 23; breast, n = 1; and sarcoma, n = 1). One to 3 tumors (mean size, 2.3 cm; range, 0.7-4.6 cm; mean SUVmax, 22.7; range, 9.5-77.1) were ablated using radiofrequency (n = 16) or microwave (n = 9) energy in a single session. Immediate-postablation enhanced CT and PET/CT scans were qualitatively evaluated by 2 reviewers independently, and the results were compared with clinical and imaging outcome at 1 y. The PET/CT scans were also analyzed to determine tissue radioactivity concentration (TRC) from 3-dimensional regions of interest in the ablation zone, the margin, and the surrounding normal liver to calculate a TRC ratio, which was then compared with outcome at 1 y. Receiver operating characteristics (ROC) were used, and the maximal-accuracy threshold in predicting recurrence was calculated. RESULTS: Eleven (44%) of the 25 tumors recurred within 1 y. Enhanced CT did not significantly correlate with recurrence (P = 0.288). Accuracy was 64% (16/25), and the area under the ROC curve was 0.601 (95% confidence interval [95% CI], 0.387-0.789). The accuracy of the qualitative analysis of (18)F-FDG PET was 92% (23/25) (P < 0.001), and the area under the ROC curve was 0.929 (95% CI, 0.740-0.990). The mean TRC ratio was 40.6 in the recurrence group (SD, 9.2; range, 29.3-53.9) and 15.9 in the group without recurrence (SD, 7.3; range, 3-27.3). A TRC ratio of 28.3 predicted recurrence at 1 y with 100% accuracy (25/25) (P < 0.001), and the area under the ROC curve was 1 (95% CI, 0.863-1). CONCLUSION: Immediate PET/CT accurately predicts the success of liver metastasis ablation at 1 y and is superior to immediate enhanced CT.
UNLABELLED: The rationale of this study was to examine whether (18)F-FDG PET/CT and contrast-enhanced CT performed immediately after percutaneous ablation of liver metastases are predictors of local treatment failure at 1 y. METHODS: This Health Insurance Portability and Accountability Act-compliant, Institutional Review Board-approved retrospective study reviewed 25 PET/CT-guided thermal ablations performed from September 2011 to March 2013 on 21 patients (11 women and 10 men; mean age, 56.8 y; range, 35-79 y) for the treatment of liver metastases (colorectal, n = 23; breast, n = 1; and sarcoma, n = 1). One to 3 tumors (mean size, 2.3 cm; range, 0.7-4.6 cm; mean SUVmax, 22.7; range, 9.5-77.1) were ablated using radiofrequency (n = 16) or microwave (n = 9) energy in a single session. Immediate-postablation enhanced CT and PET/CT scans were qualitatively evaluated by 2 reviewers independently, and the results were compared with clinical and imaging outcome at 1 y. The PET/CT scans were also analyzed to determine tissue radioactivity concentration (TRC) from 3-dimensional regions of interest in the ablation zone, the margin, and the surrounding normal liver to calculate a TRC ratio, which was then compared with outcome at 1 y. Receiver operating characteristics (ROC) were used, and the maximal-accuracy threshold in predicting recurrence was calculated. RESULTS: Eleven (44%) of the 25 tumors recurred within 1 y. Enhanced CT did not significantly correlate with recurrence (P = 0.288). Accuracy was 64% (16/25), and the area under the ROC curve was 0.601 (95% confidence interval [95% CI], 0.387-0.789). The accuracy of the qualitative analysis of (18)F-FDG PET was 92% (23/25) (P < 0.001), and the area under the ROC curve was 0.929 (95% CI, 0.740-0.990). The mean TRC ratio was 40.6 in the recurrence group (SD, 9.2; range, 29.3-53.9) and 15.9 in the group without recurrence (SD, 7.3; range, 3-27.3). A TRC ratio of 28.3 predicted recurrence at 1 y with 100% accuracy (25/25) (P < 0.001), and the area under the ROC curve was 1 (95% CI, 0.863-1). CONCLUSION: Immediate PET/CT accurately predicts the success of liver metastasis ablation at 1 y and is superior to immediate enhanced CT.
Authors: Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny Journal: J Vasc Interv Radiol Date: 2011-04-22 Impact factor: 3.464
Authors: Karin Nielsen; Aukje A J M van Tilborg; Hester J Scheffer; Martijn R Meijerink; Elly S M de Lange-de Klerk; Sybren Meijer; Emile F I Comans; M Petrousjka van den Tol Journal: Eur J Radiol Date: 2013-08-23 Impact factor: 3.528
Authors: B S Langenhoff; W J G Oyen; G J Jager; S P Strijk; Th Wobbes; F H M Corstens; T J M Ruers Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin Journal: Eur Radiol Date: 2013-10-05 Impact factor: 5.315
Authors: Constantinos T Sofocleous; Rodrigo G Nascimento; Lydia M Petrovic; David S Klimstra; Mithat Gonen; Karen T Brown; Lynn A Brody; Anne M Covey; Raymond H Thornton; Yuman Fong; Stephen B Solomon; Lawrence H Schwartz; Ronald P DeMatteo; George I Getrajdman Journal: Radiology Date: 2008-10 Impact factor: 11.105
Authors: Vincent Donckier; Jean Luc Van Laethem; Serge Goldman; Daniel Van Gansbeke; Pascale Feron; Brigitte Ickx; David Wikler; Michel Gelin Journal: J Surg Oncol Date: 2003-12 Impact factor: 3.454
Authors: Vlasios S Sotirchos; Sho Fujisawa; Efsevia Vakiani; Stephen B Solomon; Katia O Manova-Todorova; Constantinos T Sofocleous Journal: Ann Surg Oncol Date: 2019-03-04 Impact factor: 5.344
Authors: Waleed Shady; Elena N Petre; Kinh Gian Do; Mithat Gonen; Hooman Yarmohammadi; Karen T Brown; Nancy E Kemeny; Michael D'Angelica; Peter T Kingham; Stephen B Solomon; Constantinos T Sofocleous Journal: J Vasc Interv Radiol Date: 2017-12-06 Impact factor: 3.464
Authors: Francois H Cornelis; Elena N Petre; Efsevia Vakiani; David Klimstra; Jeremy C Durack; Mithat Gonen; Joseph Osborne; Stephen B Solomon; Constantinos T Sofocleous Journal: J Nucl Med Date: 2018-02-09 Impact factor: 10.057
Authors: Leigh C Casadaban; Paul J Catalano; Leslie K Lee; Hyewon Hyun; Kemal Tuncali; Victor H Gerbaudo; Paul B Shyn Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-09 Impact factor: 9.236
Authors: Joshua S Scheuermann; Janet S Reddin; Adam Opanowski; Paul E Kinahan; Barry A Siegel; Lalitha K Shankar; Joel S Karp Journal: J Nucl Med Date: 2017-03-02 Impact factor: 10.057
Authors: Francois H Cornelis; Jeremy C Durack; Simon Y Kimm; Thomas Wimmer; Jonathan A Coleman; Stephen B Solomon; Govindarajan Srimathveeravalli Journal: Cardiovasc Intervent Radiol Date: 2017-05-17 Impact factor: 2.740